ジェイファーマ株式会社 J-Pharma Co., Ltd.

  • News
  • About Us
  • Science
  • Pipeline
  • Business
  • Contact
J-Pharma presented Japanese Phase II Trial of Nanvuranlat at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2023 Nanvuranlat achieved primary endpoint in Japanese Phase II Trial for patients with refractory, advanced biliary tract cancers

News

    Archive

    • June 2025
    • May 2025
    • April 2025
    • February 2025
    • January 2025
    • December 2024
    • October 2024
    • September 2024
    • July 2024
    • June 2024
    • May 2024
    • January 2024
    • December 2023
    • October 2023
    • June 2023
    • May 2023
    • April 2023
    • March 2023
    • January 2023
    • December 2022
    • May 2022
    • April 2022
    • January 2022
    • November 2021
    • July 2021
    • March 2021
    • February 2021
    • January 2021
    • July 2020
    • June 2020
    • December 2019
    • April 2019
    • December 2018
    • July 2018
    • May 2018
    • March 2018
    • January 2018
    • September 2017
    • May 2016
    • November 2015
    • April 2015
    • February 2015
    Contact

    Please contact us from here.

    Contact

    ジェイファーマ株式会社

    J-Pharma Co., Ltd.
    8th Floor, VORT Hamamatsucho II
    1-10-11 Hamamatsucho, Minato-ku, Tokyo 105-0013, Japan
    TEL 03-6432-4270 / FAX 03-6432-4271

    • TOP PAGE
    • News
    • About Us
    • Science
    • Pipeline
    • Business
    • Contact
    • Privacy

    COPYRIGHT © J PHARMA.CO.,LTD ALL RIGHTS RESERVED

    • EN
    • JP

    COPYRIGHT © J PHARMA.CO.,LTD ALL RIGHTS RESERVED

    • TOP PAGE
    • News
    • About Us
    • Science
    • Pipeline
    • Business
    • Contact
    • Privacy
    • EN
    • JP